We are

Oyster Point

Oyster Point is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapies for diseases presenting great unmet needs whose pathophysiology includes parasympathetic pathways. Our lead candidates are in Phase 2 clinical trials for the treatment of signs and symptoms of dry eye disease.

About Us

Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories.

Jeffrey Nau

Dr. Nau has built his career on developing novel, innovative therapies for diseases of the eye, with over 15 years of experience working with biotechnology, pharmaceutical, and medical device companies. Most recently, he was VP, Clinical and Medical Affairs, at Ophthotech. Prior to that he was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Dr. Nau has raised more than $150 million in equity for start-ups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc. He has numerous patents and peer-reviewed publications

Mark Murray

Mark has been a CFO in the life science sector for over 30 years, working with senior executives and their boards. His ophthalmology experience includes the successful exits of OptiMedica and Oculeve. Mark spent over 20 years with Guidant Corporation, where he was part of the senior management team and in its $1 billion IPO thru its exit in 2006 for $27 billion (by Boston Scientific and Abbott Labs). He has helped raise over $1.6 billion in equity and over $500 million in debt for public and private companies. Mark is currently a partner at partner at FLG Partners, LLC.  He holds a BS in business administration (accounting) from San Francisco State University.

Loni Da Silva
VP, Regulatory Affairs

Loni has over 30 years of leadership experience in global regulatory affairs and strategic drug development, with more than 20 years in the ophthalmic space. She began her career at Hoffman La-Roche, and most recently served as SVP, Global Regulatory Affairs for Ophthotech, where she worked on wet and dry AMD. Loni has led global regulatory affairs for 3 start-ups and IPOs including Eyetech, Pharmasset, and Ophthotech. In addition to ophthalmology, her experience also includes oncology, antivirals, anti-infectives, hematology, pain management, and cardiology. Loni received her B.S. in microbiology from Penn State University and a M.S. in regulatory affairs from Long Island University.

Dawn Pruitt Koffler
VP, Marketing

Dawn has over 15 years of experience in sales and marketing for pharmaceutical products and medical devices. Prior to joining Oyster Point, she spent 12 years at Allergan where she served as Executive Director for consumer eye care, which included the TrueTear® device and REFRESH® brands. Before that, Dawn was Executive Director of Strategic Marketing, responsible for leading the commercial strategy for the eye care pipeline, and led consumer marketing for RESTASIS®, which earned her recognition as a Top 25 DTC marketer. She was also a member of the Global Eye Care R&D Governance Board and was the commercial lead for the integration of Oculeve and ForSight VISION5. Dawn holds a B.S. in physical therapy from California State University, Long Beach and an M.B.A. from the University of Notre Dame.


Versant, NEA back Oyster Point Pharma developing novel therapies to treat ocular surface diseases — Nov 7, 2017.

Oyster Point Pharmaceuticals Inc., which is developing novel therapies for dry eye and other diseases of the ocular surface, today announced the completion of a $22 million Series A financing led by New Enterprise Associates and Versant Ventures. The proceeds from the round will fund Oyster Point's differentiated products through Phase II clinical trials.

Read More

Contact Us

Oyster Point Pharma, Inc
700 Alexander Park Drive, Suite 301,
Princeton, New Jersey 08540, United States